Search details
1.
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
Haemophilia
; 28(4): 548-556, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35475308
2.
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Haemophilia
; 27(6): 911-920, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34614267
3.
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Haemophilia
; 27(6): 921-931, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34636112
4.
Mechanisms of action of an investigational new freeze-dried platelet-derived hemostatic product.
J Thromb Haemost
; 22(3): 686-699, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38072376
5.
Characterization of a canine freeze-dried platelet-derived hemostatic agent: A preclinical model for surgical and traumatic hemorrhage.
Thromb Res
; 238: 67-77, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38678865
6.
Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.
J Manag Care Spec Pharm
; 28(5): 518-527, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35343812
7.
Safety and immunogenicity of recombinant human thrombin: a pooled analysis of results from 10 clinical trials.
Pharmacotherapy
; 32(11): 998-1005, 2012 Nov.
Article
in English
| MEDLINE | ID: mdl-23108631
8.
Immunogenicity and safety of re-exposure to recombinant human thrombin in surgical hemostasis.
J Am Coll Surg
; 213(6): 722-7, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-21958507
9.
Recombinant human thrombin: safety and immunogenicity in pediatric burn wound excision.
J Pediatr Surg
; 46(10): 1992-9, 2011 Oct.
Article
in English
| MEDLINE | ID: mdl-22008340
10.
Persistence of antibodies to the topical hemostat bovine thrombin.
J Am Coll Surg
; 211(6): 798-803, 2010 Dec.
Article
in English
| MEDLINE | ID: mdl-20980172
11.
Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin.
J Am Coll Surg
; 210(2): 199-204, 2010 Feb.
Article
in English
| MEDLINE | ID: mdl-20113940
12.
Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting.
J Burn Care Res
; 30(3): 371-9, 2009.
Article
in English
| MEDLINE | ID: mdl-19349898
13.
Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.
Patient Saf Surg
; 3(1): 8, 2009 May 22.
Article
in English
| MEDLINE | ID: mdl-19463180
14.
A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis.
J Am Coll Surg
; 209(1): 68-74, 2009 Jul.
Article
in English
| MEDLINE | ID: mdl-19651065
15.
Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding.
Ann Surg Innov Res
; 3: 14, 2009 Nov 19.
Article
in English
| MEDLINE | ID: mdl-19925675
16.
A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures.
J Vasc Surg
; 47(6): 1266-73, 2008 Jun.
Article
in English
| MEDLINE | ID: mdl-18440754
Results
1 -
16
de 16
1
Next >
>>